Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non‐small cell lung cancer after second‐line chemotherapy treatment: a …
D Zhang, C Zhang, J Huang, Y Guan, Q Guo - Thoracic cancer, 2018 - Wiley Online Library
Background This study was designed to assess the clinical efficacy and toxicity of apatinib
(YN968D1) as third or subsequent‐line treatment for stage III/IV non‐small cell lung cancer …
(YN968D1) as third or subsequent‐line treatment for stage III/IV non‐small cell lung cancer …
Clinical response to apatinib monotherapy in advanced non‐small cell lung cancer
J Xu, X Liu, S Yang, X Zhang… - Asia‐Pacific journal of …, 2018 - Wiley Online Library
Aim Apatinib, an oral tyrosine kinase inhibitor mainly targeting VEGFR‐2, exerts both
antiangiogenesis and antiproliferation effects. Apatinib shows clinical benefit in advanced …
antiangiogenesis and antiproliferation effects. Apatinib shows clinical benefit in advanced …
Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report
Y Peng, H Cui, Z Liu, D Liu, F Liu, Y Song… - OncoTargets and …, 2017 - Taylor & Francis
Lung adenocarcinoma is the most common pathological pattern of lung cancer. During the
past decades, a number of targeted agents have been explored to treat advanced lung …
past decades, a number of targeted agents have been explored to treat advanced lung …
Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study
G Yang, H Xu, L Yang, F Xu, S Zhang, Y Yang, Y Wang - Lung Cancer, 2020 - Elsevier
Objectives Apatinib showed efficacy in non-small cell lung cancer (NSCLC). We conducted
this phase II clinical study to assess the efficacy and safety of apatinib in combination with …
this phase II clinical study to assess the efficacy and safety of apatinib in combination with …
An update on molecularly targeted therapies in second-and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents
M Majem, C Pallares - Clinical and Translational Oncology, 2013 - Springer
Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors
(gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell …
(gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell …
A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-Squamous Non–Small-Cell Lung Cancer
F Wu, S Zhang, A Xiong, G Gao, W Li, W Cai, C Su… - Clinical Lung Cancer, 2018 - Elsevier
Objectives Apatinib exhibits broad-spectrum antitumor activities by selectively inhibiting
vascular endothelial growth factor receptor-2. This study evaluated the efficacy and safety of …
vascular endothelial growth factor receptor-2. This study evaluated the efficacy and safety of …
A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC
M Huang, Y Gong, J Zhu, Y Qin, F Peng, L Ren… - Investigational New …, 2020 - Springer
Objective Apatinib is an oral small molecule anti-angiogenic drug. This phase I study aimed
to establish the feasible dose of apatinib in combination with pemetrexed plus carboplatin as …
to establish the feasible dose of apatinib in combination with pemetrexed plus carboplatin as …
Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non–Small Cell Lung …
T Hirano, H Yasuda, J Hamamoto, S Nukaga… - Molecular cancer …, 2018 - AACR
Multiple epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) have
been developed to effectively inhibit EGFR-derived signals in non–small cell lung cancer …
been developed to effectively inhibit EGFR-derived signals in non–small cell lung cancer …
Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled …
TT Zhang, RM Wang, Z Yang, GB Chen - Clinical and Translational …, 2016 - Springer
Background The strategy of dual inhibiting epidermal growth factor receptor (EGFR) and
vascular endothelial growth factor (VEGF) pathways has been extensively investigated in …
vascular endothelial growth factor (VEGF) pathways has been extensively investigated in …
[HTML][HTML] P1. 16-01 amivantamab and lazertinib in treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)
BC Cho, SH Lee, JY Han, EK Cho, JS Lee… - Journal of Thoracic …, 2022 - jto.org
Methods The treatment-naive cohort enrolled patients who had NSCLC characterized by
either EGFR exon 19 deletion (ex19del) or L858R activating mutations. Patients received …
either EGFR exon 19 deletion (ex19del) or L858R activating mutations. Patients received …